Fig. 5: GRAMD1A promoted proliferation of CRC. | Cell Death & Differentiation

Fig. 5: GRAMD1A promoted proliferation of CRC.

From: KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression

Fig. 5

A Immunofluorescence staining of GRAMD1A expression in KRAS mutant and wild-type CRC tissues and normal colon tissues. Scale bar: up panel, 100 μm; down panel 25 μm. B Statistical immunofluorescence results of GRAMD1A expression in KRAS mutant and wild-type CRC tissues and normal colon tissues. C Kaplan–Meier survival curves contrasting difference between CRC patients in advanced stages with low and high GRAMD1A expression from TCGA datasets. Proliferation of D HCT116 and E DLD1 cells after knocking down GRAMD1A analyzed by CCK8 assay. n  =  4. F, G Tumor growth of HCT116 and DLD1 cells after knocking down GRAMD1A evaluated by F colony formation assay and G statistical analysis. n  =  3. Proliferation of H HCT116 and I DLD1 cells after GRAMD1A overexpression with or without oxamate treatment analyzed by CCK8 assay. n  =  4. Tumor growth of HCT116 and DLD1 cells after GRAMD1A overexpression with or without oxamate treatment analyzed by J colony formation assay and K statistical analysis. n  =  3. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, determined by two-tailed Welch’s t-test (left) or Student’s t-test (right) (B), Log-rank test (C) and one-way ANOVA (D, E, G, H, I, K).

Back to article page